Compare BridgeBio Pharma Inc (BBIO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs PepsiCo, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while PepsiCo, Inc. trades at $138.04 (market cap $187.99B). The key difference: PepsiCo, Inc. is far larger — about 11.3× BridgeBio Pharma Inc's market cap, and PepsiCo, Inc. pays a 4.3% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PEP | |
|---|---|---|
Market Cap | $16.61B | $187.99B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $170.44 |
52-Week Low | $47.29 | $134.95 |
Enterprise Value | $18.16B | $230.48B |
Dividend Yield | — | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93 billion in 2025, with a net income margin of 10.78%, and has beaten EPS estimates in recent quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts anticipate Q1 2026 results.
The outlook is mixed: strong profitability and dividend yield near 4% support value, but price sensitivity and competitive pressures pose risks. Analyst consensus is a 'Hold' with a $158.79 price target, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
